doi: 10.3389/fped.2023.1263836 Received 20 July 2023 Accepted 21 August 2023 Published 12 September 2023 Volume 11 - 2023 Edited by Paul Henderson, University of Edinburgh, United Kingdom Reviewed by Tudor Lucian Pop, University of Medicine and Pharmacy Iuliu Hatieganu, Romania Bin Wang, Shenzhen Childrens Hospital, China Updates Copyright 2023 Jiachen, Paul Kwong Hang, Kenneth Kak Yuen and Vincent Chi Hang
Designed for elite research environments, these compounds offer the precision needed to study how the body maintains resilience against environmental and biological stressors
Semaglutide, the main ingredient in Ozempic and Wegovy, mimics a natural hormone called glucagon-like peptide-1
This complex microenvironment renders it susceptible to a range of disorders, including peptic ulcers, inflammatory bowel disease (IBD), pancreatic cancer (PC), colorectal cancer (CRC), and metabolic diseases such as diabetes [3,4,5,6]